Compare INBX & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INBX | CDNA |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.7M | 1.1B |
| IPO Year | 2024 | 2007 |
| Metric | INBX | CDNA |
|---|---|---|
| Price | $109.32 | $19.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $150.00 | $28.00 |
| AVG Volume (30 Days) | 586.3K | ★ 733.8K |
| Earning Date | 05-15-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | $1,300,000.00 | ★ $48,324,000.00 |
| Revenue This Year | N/A | $16.01 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | ★ N/A | $409.60 |
| Revenue Growth | ★ 550.00 | 18.93 |
| 52 Week Low | $12.80 | $10.96 |
| 52 Week High | $155.29 | $23.24 |
| Indicator | INBX | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 50.41 | 47.72 |
| Support Level | $69.30 | $16.63 |
| Resistance Level | $155.29 | $21.20 |
| Average True Range (ATR) | 13.20 | 1.33 |
| MACD | -3.55 | -0.22 |
| Stochastic Oscillator | 23.22 | 38.34 |
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.